Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/78141
Title: | Prospective evaluation of plasma Epstein-Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma | Authors: | Ma, B Hui, EP King, A Leung, SF Kam, MKM Mo, F Li, L Wang, K Loong, H Wong, A Chan, CML Chan, KCA Wong, SCC Lo, YMD Chan, ATC |
Issue Date: | 2018 | Source: | British journal of cancer, 2018, v. 118, no. 8, p. 1051-1055 | Abstract: | Background: Plasma Epstein-Barr virus (pEBV) DNA and fluorodeoxyglucose positron emission (PET) reflect tumour burden in advanced NPC. This study hypothesised that a dual endpoint based on assessing pEBV DNA clearance and PET response could predict early drug response. Methods: Eligible patients underwent a computed tomography (CT) scan and dual PET-CT at baseline, a PET-CT at 4 weeks, and then a CT scan at 10 weeks after starting palliative or induction chemotherapy. Plasma EBV DNA clearance was determined. Results: Fifty-eight out of 70 enrolled patients completed all imaging and 50/58 had falling pEBV DNA level, which allowed calculation of the clearance. At a median follow-up of 29.1 months, the dual endpoint (pEBV DNA clearance ≤ 10 days and > 50% drop in sum of SUVmax of target lesions) was an independent indicator of overall survival (hazard ratio (HR) = 0.135, 95% CI = 0.039 to 0.466, p = 0.0015) and progression-free survival (HR = 0.136, 95% CI = 0.048 to 0.385, p = 0002). This dual endpoint could predict subsequent response by Response Evaluation Criteria In Solid Tumours (RECIST) criteria at 10 weeks after chemotherapy. Conclusions: Early PET-CT response and pEBV DNA clearance could predict survival and subsequent response. This dual endpoint is an innovative tool for assessing early drug response. |
Publisher: | Nature Publishing Group | Journal: | British journal of cancer | ISSN: | 0007-0920 | EISSN: | 1532-1827 | DOI: | 10.1038/s41416-018-0026-9 | Rights: | © Cancer Research UK 2018 This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The following publication Ma, B., Hui, E.P., King, A. et al. (2018). Prospective evaluation of plasma Epstein–Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma. British journal of cancer, 118(8), 1051–1055 is available at https://doi.org/10.1038/s41416-018-0026-9 |
Appears in Collections: | Journal/Magazine Article |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Ma_Prospective_Evaluation_Plasma.pdf | 352.47 kB | Adobe PDF | View/Open |
Page views
117
Last Week
1
1
Last month
Citations as of Mar 24, 2024
Downloads
30
Citations as of Mar 24, 2024
SCOPUSTM
Citations
20
Last Week
0
0
Last month
Citations as of Mar 28, 2024
WEB OF SCIENCETM
Citations
18
Last Week
0
0
Last month
Citations as of Mar 28, 2024
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.